These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1354 related articles for article (PubMed ID: 16921036)

  • 41. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
    Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
    Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical characteristics and the prognosis of childhood rhabdomyosarcoma in 60 patients treated at a single institute.
    Company F; Pedram M; Rezaei N
    Acta Med Iran; 2011; 49(4):219-24. PubMed ID: 21713731
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
    Oberlin O; Rey A; Sanchez de Toledo J; Martelli H; Jenney ME; Scopinaro M; Bergeron C; Merks JH; Bouvet N; Ellershaw C; Kelsey A; Spooner D; Stevens MC
    J Clin Oncol; 2012 Jul; 30(20):2457-65. PubMed ID: 22665534
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma.
    Dantonello TM; Int-Veen C; Winkler P; Leuschner I; Schuck A; Schmidt BF; Lochbuehler H; Kirsch S; Hallmen E; Veit-Friedrich I; Bielack SS; Niggli F; Kazanowska B; Ladenstein R; Wiebe T; Klingebiel T; Treuner J; Koscielniak E
    J Clin Oncol; 2008 Jan; 26(3):406-13. PubMed ID: 18202417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS).
    Smith LM; Anderson JR; Coffin CM
    Med Pediatr Oncol; 2002 Jun; 38(6):398-404. PubMed ID: 11984800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
    Arndt CA; Stoner JA; Hawkins DS; Rodeberg DA; Hayes-Jordan AA; Paidas CN; Parham DM; Teot LA; Wharam MD; Breneman JC; Donaldson SS; Anderson JR; Meyer WH
    J Clin Oncol; 2009 Nov; 27(31):5182-8. PubMed ID: 19770373
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Group II rhabdomyosarcoma and rhabdomyosarcomalike tumors: is radiotherapy necessary?
    Schuck A; Mattke AC; Schmidt B; Kunz DS; Harms D; Knietig R; Treuner J; Koscielniak E
    J Clin Oncol; 2004 Jan; 22(1):143-9. PubMed ID: 14701776
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
    Dome JS; Cotton CA; Perlman EJ; Breslow NE; Kalapurakal JA; Ritchey ML; Grundy PE; Malogolowkin M; Beckwith JB; Shamberger RC; Haase GM; Coppes MJ; Coccia P; Kletzel M; Weetman RM; Donaldson M; Macklis RM; Green DM
    J Clin Oncol; 2006 May; 24(15):2352-8. PubMed ID: 16710034
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Results of treatment of rhabdomyosarcomas (RMS) in children. A report of the Cooperative Soft Tissue Sarcoma Study (CWS-81) of the Society of Pediatric Oncology].
    Treuner J; Kaatsch P; Anger Y; Seipp A; Spaar HJ; Gerein V; Suder J; Niethammer D
    Klin Padiatr; 1986; 198(3):208-17. PubMed ID: 3523026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
    Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
    Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Treatment of rhabdomyosarcoma at the National Cancer Center Hospital].
    Beppu Y; Fukuma H; Chuma H; Ise T; Ohira M
    Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 2):1603-13. PubMed ID: 3592704
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Rhabdomyosarcoma].
    Hosoi H; Tsuchiya K; Sugimoto T
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):181-6. PubMed ID: 17301524
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group.
    Chiles MC; Parham DM; Qualman SJ; Teot LA; Bridge JA; Ullrich F; Barr FG; Meyer WH;
    Pediatr Dev Pathol; 2004; 7(6):583-94. PubMed ID: 15630526
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV.
    Pappo AS; Meza JL; Donaldson SS; Wharam MD; Wiener ES; Qualman SJ; Maurer HM; Crist WM
    J Clin Oncol; 2003 Feb; 21(4):638-45. PubMed ID: 12586800
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Joshi D; Anderson JR; Paidas C; Breneman J; Parham DM; Crist W;
    Pediatr Blood Cancer; 2004 Jan; 42(1):64-73. PubMed ID: 14752797
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
    J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors.
    Krasin MJ; Rodriguez-Galindo C; Billups CA; Davidoff AM; Neel MD; Merchant TE; Kun LE
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):830-8. PubMed ID: 15465200
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group.
    Yock TI; Krailo M; Fryer CJ; Donaldson SS; Miser JS; Chen Z; Bernstein M; Laurie F; Gebhardt MC; Grier HE; Tarbell NJ;
    J Clin Oncol; 2006 Aug; 24(24):3838-43. PubMed ID: 16921035
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Analysis of prognostic factors in rhabdomyosarcoma. Preliminary univariate and multivariate results of the Cooperative Soft Tissue Sarcoma Study (CWS-81)].
    Suder J; Stienen U; Kaatsch P; Harms D; Schmidt D; Spaar HJ; Treuner J
    Klin Padiatr; 1986; 198(3):218-23. PubMed ID: 3523027
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic factors in children with rhabdomyosarcoma.
    Gehan EA; Glover FN; Maurer HM; Sutow WW; Hays DM; Lawrence W; Newton WA; Soule EH
    Natl Cancer Inst Monogr; 1981 Apr; (56):83-92. PubMed ID: 7029299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.